# Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

> **NCT07683026** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 255 (estimated)

## Conditions studied

- Type 1 Diabetes (T1D)

## Interventions

- **DRUG:** Golimumab
- **DRUG:** Placebo (matching golimumab)

## Key facts

- **NCT ID:** NCT07683026
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-08
- **Primary completion:** 2032-09-01
- **Final completion:** 2032-09-01
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683026, "Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*